NanoViricides Story

<div class='circular--portrait' style='background:#9CBEFD;color: #ffffff;font-size:4em;'>NI</div>
NNVC -- USA Stock  

USD 4.43  0.60  15.67%

NanoViricides Inc Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 17.6 Million. The current year Average Equity is expected to grow to about 17.8 M, whereas Net Income Per Employee is forecasted to decline to (1.8 M). NanoViricides NEW is scheduled to announce its earnings tomorrow. The stock is undergoing an active downward rally. While some generation-Y investors are indifferent towards healthcare space, it makes sense to go over NanoViricides Inc NEW using its fundamentals . We will evaluate why we are still confident in anticipation of a recovery. Will investors continue to hold, or should we expect a sell-off?
Published over three months ago
View all stories for NanoViricides Inc | View All Stories
Are NanoViricides Inc (NYSEMKT:NNVC) weak basic indicators contributing to the current slip?
NanoViricides Inc is UNDERVALUED at 6.17 per share with modest projections ahead. NanoViricides NEW has Sharpe Ratio of -0.0364, which conveys that the firm had -0.0364% of return per unit of risk over the last month. Macroaxis standpoint towards estimating the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. NanoViricides Inc exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify NanoViricides Inc NEW risk adjusted performance of (0.06), and Mean Deviation of 5.39 to check out the risk estimate we provide.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include NanoViricides Inc income statement, its balance sheet, and the statement of cash flows. Potential NanoViricides Inc investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although NanoViricides Inc investors may use each financial statement separately, they are all related. The changes in NanoViricides Inc's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NanoViricides Inc's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages. The goal of NanoViricides Inc fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of NanoViricides Inc performance into the future periods or doing a reasonable stock valuation. The intrinsic value of NanoViricides Inc shares is the value that is considered the true value of the share. If the intrinsic value NanoViricides is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares NanoViricides Inc. Please read more on our fundamental analysis page.

How important is NanoViricides Inc's Liquidity

NanoViricides Inc financial leverage refers to using borrowed capital as a funding source to finance NanoViricides Inc NEW ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. NanoViricides Inc financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between NanoViricides Inc's total debt and its cash.

How NanoViricides utilizes its cash?

To perform a cash flow analysis of NanoViricides Inc, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NanoViricides Inc is receiving and how much cash it distributes out in a given period. The NanoViricides Inc cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NanoViricides Inc Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (6 Million)

Payment of 38472 shares by Eugene Seymour of NanoViricides Inc subject to Rule 16b-3

Legal trades by NanoViricides Inc insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
NanoViricides insider trading alert for payment of common stock par value $0.001 per share by Eugene Seymour, Chief Executive Officer, on 14th of December 2020. This event was filed by Nanoviricides Inc with SEC on 2015-09-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Another angle On NanoViricides Inc

The current slip in stock price may encourage investors to take a closer look at the firm as it closed today at a share price of 4.21 on 1,625,589 in trading volume. The company executives have failed to build on market volatilities in August. However, diversifying your overall positions with NanoViricides Inc may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.66. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the NanoViricides NEW partners.

Asset Utilization

One of the ways to look at asset utilization of NanoViricides is to check how much profit was generated for every dollar of assets it reports. NanoViricides Inc NEW secures a negative usage of assets of -32.63 %, losing $0.33 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of NanoViricides Inc NEW shows how discouraging it operates for each dollar spent on its assets.

Assets Non Current
10.5 M
Current Assets2.61 Million19.15
Assets Non Current10.53 Million77.3

Will NanoViricides Inc bounce back in October?

Current value at risk indicator falls down to -9.68. Possible price jump? NanoViricides Inc NEW is displaying above-average volatility over the selected time horizon. Investors should scrutinize NanoViricides Inc NEW independently to ensure intended market timing strategies are aligned with expectations about NanoViricides Inc volatility.

Whereas many other companies in the biotechnology industry are either recovering or due for a correction, NanoViricides Inc may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the current economy, it is better to hold off any trading of NanoViricides as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NanoViricides Inc.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of NanoViricides Inc NEW. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to